C
티앤알바이오팹
246710KOSDAQ기초 의약물질 제조업47.5 / 100
Reference Date: 2026-04-13
Financial Score13.0 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 3.7% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
T&N Biofabrication focuses on regenerative medicine, bio-surgical solutions, and cosmetics, leveraging its 3D bioprinting systems, bioinks, and biodegradable scaffolds. The company is developing 3D organoids and cell therapies through long-term R&D while also advancing short-term revenue streams via bio-surgical solutions.
Number of Employees
82people
Average Salary
51.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 33.454.0Point
PBR
6.48Industry Average 2.030.0Point
3.2x industry avg (risky)
ROE
-147.79Industry Average -4.293.5Point
34.4x industry avg (excellent)
Debt Ratio
228.72Industry Average 6.610.0Point
34.6x industry avg (risky)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲223.5% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲13.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -71.2% (declining, 3yr)
Detailed News Sentiment
3 totalPositive 0Neutral 0Negative 0
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (58%)
Current 3,145Won52-week high 4,53552-week low 1,194
1-month return2.0Point
1m -3.68% (slight drop)
Volume trend5.0Point
Volume increasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-04-09
- Neutral주식등의대량보유상황보고서(일반)2026-04-01
- Neutral정기주주총회결과2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18